Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R that inhibits the interaction between BAFF and BAFF-R, blocking BAFF-mediated apoptosis protection. Ianalumab exhibits antibody-dependent cytotoxicity (ADCC) and activates effector cells via the immune receptor tyrosine activation motif (ITAM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $222 | In Stock | |
5 mg | $553 | In Stock | |
10 mg | $796 | In Stock | |
25 mg | $1,220 | In Stock | |
50 mg | $1,650 | In Stock | |
100 mg | $2,220 | In Stock |
Description | Ianalumab (VAY-736) is a decarboxylated humanized antibody against BAFF-R that inhibits the interaction between BAFF and BAFF-R, blocking BAFF-mediated apoptosis protection. Ianalumab exhibits antibody-dependent cytotoxicity (ADCC) and activates effector cells via the immune receptor tyrosine activation motif (ITAM). |
In vitro | Ianalumab (0.1 μg/mL; 72 h) demonstrates significant antibody-dependent cell-mediated cytotoxicity (ADCC) against natural killer cells in chronic lymphocytic leukemia (CLL), enhancing cytokine production[1]. |
In vivo | Ianalumab (total dose: 100 mg/kg; once a week; for 2 weeks) increases the survival rate in a mouse model of chronic lymphocytic leukemia (CLL)[1]. Ianalumab (10 mg/kg; once a week; for 6 weeks), when modulated with Ibrutinib, demonstrates enhanced functionality of NK cells[1]. |
Alias | VAY-736 |
Molecular Weight | 146.44 kDa |
Cas No. | 1929549-92-7 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.